MENA: revenue of anti-diabetes drugs 2028

The revenue in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in MENA was forecast to continuously increase between 2024 and 2028 by in total 0.5 billion U.S. dollars (+21.46 percent). After the twelfth consecutive increasing year, the indicator is estimated to reach 2.84 billion U.S. dollars and therefore a new peak in 2028. Notably, the revenue of the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market was continuously increasing over the past years.

Revenue of anti-diabetes drugs in the Middle East and North Africa region from 2016 to 2028 (in billion U.S. dollars)

Characteristic	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Citation formats